USFDA raises concern over drug production process at Cadila

Tags: News
The US Food and Drug Administration (FDA) has expressed concerns over the manufacturing process of at least one product at drugmaker Cadila Healthcare Ltd's Moraiya facility, two sources with direct knowledge of the matter said.

The FDA has not expressed concerns over the entire facility, said the sources. The US agency communicated its concern to Cadila in a Form 483, a letter in which the agency typically outlines violations of standard manufacturing practices.

Once the Form 483 is sent, the company has 15 days to respond before the FDA takes any further action.

The FDA inspected the Moraiya plant, based in Gujarat, in the second week of July, one of the sources said.

The sources declined to be named as the information is not public yet. A Cadila spokeswoman declined to comment.

Cadila's shares dropped as much as 10.5% on Thursday and were trading down 5.3% to Rs 1,106.50 at 1:01 pm., while the broader Nifty was down 0.22%.

EDITORIAL OF THE DAY

  • A sexist construction of women denies the man the chance of being a man, fully

    Salman Khan’s recent remark comparing what he felt when he walked out of the wrestling ring in his film Sultan with “a raped woman walking out”

FC NEWSLETTER

Stay informed on our latest news!

TODAY'S COLUMNS

Tushar Gandhi

The shame of rejecting our women

Recently, three young women broke into the elite male basti­on ...

Kuruvilla Pandikattu

Free food operation for the needy

Food is obviously a basic necessity. Recently a nob­le ...

Shona Adhikari

How Brexit will affect the world of art

The results of UK’s exit vote has led to a ...